These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9056584)

  • 41. Estimating treatment means in a mixed-effect ANOVA model for bioequivalence studies.
    Hsuan FC
    Biometrics; 1993 Sep; 49(3):703-13. PubMed ID: 8241367
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Consideration of individual bioequivalence.
    Anderson S; Hauck WW
    J Pharmacokinet Biopharm; 1990 Jun; 18(3):259-73. PubMed ID: 2380920
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tolerance intervals for assessing individual bioequivalence.
    Brown EB; Iyer HK; Wang CM
    Stat Med; 1997 Apr; 16(7):803-20. PubMed ID: 9131767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Statistical issues in bioequivalence [correction of bioequivalance].
    Senn S
    Stat Med; 2001 Sep 15-30; 20(17-18):2785-99. PubMed ID: 11523083
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population/Individual Bioequivalence Working Group. Food and Drug Administration.
    Hauck WW; Hyslop T; Chen ML; Patnaik R; Williams RL
    Pharm Res; 2000 Apr; 17(4):375-80. PubMed ID: 10870978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A practical approach for evaluating population and individual bioequivalence.
    Gould AL
    Stat Med; 2000 Oct; 19(20):2721-40. PubMed ID: 11033571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Individual bioequivalence--a regulatory update.
    Chen ML
    J Biopharm Stat; 1997 Mar; 7(1):5-11. PubMed ID: 9056581
    [No Abstract]   [Full Text] [Related]  

  • 50. Experimental design and statistical methods for classical and bioequivalence hypothesis testing with an application to dairy nutrition studies.
    Tempelman RJ
    J Anim Sci; 2004; 82 E-Suppl():E162-172. PubMed ID: 15471796
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of average, population and individual bioequivalence in two- and four-period crossover studies.
    Wijnand HP
    Comput Methods Programs Biomed; 2003 Jan; 70(1):21-35. PubMed ID: 12468124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Robustness of bioequivalence procedures under Box-Cox alternatives.
    Xiao W; Barron AM; Liu J
    J Biopharm Stat; 1997 Mar; 7(1):135-55. PubMed ID: 9056594
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A retrospective assessment of the 75/75 rule in bioequivalence.
    Dobbins TW; Thiyagarajan B
    Stat Med; 1992 Jul; 11(10):1333-42. PubMed ID: 1518994
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Group sequential extensions of a standard bioequivalence testing procedure.
    Gould AL
    J Pharmacokinet Biopharm; 1995 Feb; 23(1):57-86. PubMed ID: 8576845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The U.S. draft guidance regarding population and individual bioequivalence approaches: comments by a research-based pharmaceutical company.
    Hauschke D; Steinijans VW
    Stat Med; 2000 Oct; 19(20):2769-74. PubMed ID: 11033574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Between-Batch Bioequivalence (BBE): a Statistical Test to Evaluate In Vitro Bioequivalence Considering the Between-Batch Variability.
    Bodin J; Liandrat S; Kocevar G; Petitcolas C
    AAPS J; 2020 Sep; 22(5):119. PubMed ID: 32910283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Individual bioequivalence. New concepts in the statistical assessment of bioequivalence metrics. FDA Individual Bioequivalence Working Group.
    Patnaik RN; Lesko LJ; Chen ML; Williams RL
    Clin Pharmacokinet; 1997 Jul; 33(1):1-6. PubMed ID: 9250419
    [No Abstract]   [Full Text] [Related]  

  • 58. Towards a practical strategy for assessing individual bioequivalence. Food and Drug Administration Individual Bioequivalence Working Group.
    Schall R; Williams RL
    J Pharmacokinet Biopharm; 1996 Feb; 24(1):133-49. PubMed ID: 8827586
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measuring switchability and prescribability: when is average bioequivalence sufficient?
    Hauck WW; Anderson S
    J Pharmacokinet Biopharm; 1994 Dec; 22(6):551-64. PubMed ID: 7473081
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The structural error-in-equation model to evaluate individual bioequivalence.
    Carrasco JL; Jover L
    Biom J; 2005 Oct; 47(5):623-34. PubMed ID: 16385903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.